Healthcare / BiotechnologyTaipei Exchange
$121.50
-2.50 (-2.02%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-343.2M · quality 78.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
20/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$20.3B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-22.6%
↓Gross Margin
61.0%
↑Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+10.4%
FCF CAGR
—
FCF margin
-1008.0%
FCF / Net income
1.06x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $35.8M · net income $-340.5M · FCF $-361.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $35.8M | $35.8M | $39.2M | $56.9M | $26.6M |
| Net Income | $-340.5M | $-340.5M | $-424.8M | $-238.0M | $-494.7M |
| EBITDA | $-335.2M | $-335.2M | $-428.2M | $-226.7M | $-482.1M |
| EPS | -2.05 | -2.05 | -2.60 | -1.47 | -3.04 |
| Gross Margin | 61.0% | 61.0% | 45.2% | 72.9% | 54.7% |
| Operating Margin | -930.8% | -930.8% | -911.6% | -660.0% | -1148.3% |
| Net Margin | -950.4% | -950.4% | -1084.9% | -418.2% | -1856.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 |
| Current Ratio | 7.37 | 7.37 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-361.2M | $-361.2M | $-296.8M | $-343.2M | $-302.7M |
| Returns | |||||
| ROE | -22.6% | -22.6% | -22.2% | -17.0% | -30.4% |
| Valuation | |||||
| P/B | 13.38 | 13.38 | 20.18 | 8.06 | 3.85 |
| Growth & Yield | |||||
| Revenue Growth | -8.5% | -8.5% | -31.2% | 113.6% | — |
| EPS Growth | 21.2% | 21.2% | -76.9% | 51.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-18.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-2.60 → -2.05
Residual
-18.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.